Related Experiment Videos
Medroxyprogesterone acetate exacerbates glutamate excitotoxicity.
Jon Nilsen1, Alison Morales, Roberta Diaz Brinton
1Department of Molecular Pharmacology and Toxicology, University of Southern California, Pharmaceutical Sciences Center, Los Angeles, CA 90089, USA. jnilsen@usc.edu
Summary
Medroxyprogesterone acetate (MPA) does not protect neurons and can worsen excitotoxicity, unlike progesterone. MPA's ineffectiveness in neuroprotection is independent of formulation or timing, impacting central nervous system vulnerability.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Progesterone demonstrates neuroprotective properties.
- Medroxyprogesterone acetate (MPA), a synthetic progestin, has shown a lack of neuroprotection and can antagonize the effects of 17beta-estradiol (E2).
- Understanding MPA's effects is crucial for developing effective hormone therapies against neurodegeneration.
Purpose of the Study:
- To investigate if MPA formulation, chemical properties, or administration timing influences its neuroprotective efficacy.
- To evaluate MPA's impact on primary hippocampal neuron survival under various conditions.
- To determine if MPA exacerbates neurotoxicity.
Main Methods:
- Primary hippocampal neuron cultures were used to assess survival.
- MPA was tested in different formulations (crystalline and Depo-Provera) and administration paradigms (prevention and treatment).
- Medroxyprogesterone (without acetate) was compared to MPA.
- Glutamate excitotoxicity models were employed to evaluate MPA's effect on neuron death, using live/dead cell counts and TUNEL assays.
Main Results:
- Both crystalline MPA and Depo-Provera formulations were ineffective in promoting neuronal survival.
- MPA demonstrated no efficacy in either prevention or treatment modes of exposure.
- Medroxyprogesterone was also ineffective, indicating the acetate group is not responsible for MPA's lack of neuroprotection.
- MPA pretreatment significantly increased neuron death (40%) under glutamate excitotoxicity.
Conclusions:
- MPA formulation and administration timing do not alter its lack of neuroprotective effects.
- MPA does not protect neurons and can enhance excitotoxic neuronal death.
- The findings suggest that progestin formulations in hormone therapy can influence central nervous system vulnerability to neurodegenerative insults.